Skip to contentpdufa.bio
Home › Decisions › NVS 2026-11-16

COSENTYX (secukinumab) FDA approval for polymyalgia rheumatica: Nov 16, 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET
✓ APPROVED

COSENTYX (secukinumab) was approved by the FDA on November 16, 2026 for adults with polymyalgia rheumatica with an inadequate response to corticosteroids or who cannot tolerate a corticosteroid taper.

Verified against: FDA action day November 16, 2026 (BLA 125504 SUPPL-101 (FDA letter)) · Goal date: none on record.

This page was first committed to pdufa.bio's public repository on Nov 20, 2026, 4:09 AM ET (public commit 2b423a8). Dates on this page are the FDA's and the sponsor's; this line is ours.

Run-up into the decision (T-120 → T+3)

FDA decision 11/16/26$164.98$137.165/27/26FDA decision 11/16/26$164.98$137.165/27/26
Daily close, T-120 (5/27/26) through T+3. Run-up high $164.98 on 11/4/26, low $137.16 on 9/11/26 (T-120 to T-1). FDA decision 11/16/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-11-16
OutcomeApproved
Drug / candidateCOSENTYX (secukinumab)
IndicationAdults with polymyalgia rheumatica with an inadequate response to corticosteroids or who cannot tolerate a corticosteroid taper
CompanyNovartis
Market-cap tierLarge
120-day run-up (T-120→T-1)+6.4%
Decision-day move-0.2%
Move measured on2026-11-16 close, against the 2026-11-13 close
Cohort decision-day move (history)1.0% median (n=647)

The FDA's supplement approval letter for BLA 125504 supplement 101, signed November 16, 2026 (FDA letter), adds a new indication for the treatment of adult patients with polymyalgia rheumatica (PMR); the letter states that the supplemental application was received on January 16, 2026. openFDA's Drugs@FDA data lists the approval under November 17; the date here is the letter's own signature date. Novartis announced the approval that evening (US Eastern time; its release is datelined Basel, November 17) for Cosentyx 150 mg in adults with PMR who have had an inadequate response to corticosteroids or who cannot tolerate a corticosteroid taper (Novartis, November 17, 2026). We hold no publicly disclosed PDUFA goal date for this supplement, so no early or late margin is given.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: FDA approval letter, BLA 125504 S-101

FDA record of the action: the FDA approved on November 16, 2026, per BLA 125504 SUPPL-101 (FDA letter). The sponsor announced it the same day. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.

Questions

Was COSENTYX (secukinumab) approved by the FDA?

Yes. The FDA approved the application for COSENTYX (secukinumab) on November 16, 2026, per the FDA's own record. The primary source is linked on this page.

Which company is behind COSENTYX (secukinumab)?

COSENTYX (secukinumab) is a Novartis (NVS) program. The FDA decision came on November 16, 2026; the FDA's own record of the decision is linked on this page.

How did NVS stock react to the FDA decision?

NVS moved -0.2%, measured as the 2026-11-16 close against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.

Is Cosentyx approved for polymyalgia rheumatica?

Yes. The FDA's approval letter, signed November 16, 2026, adds polymyalgia rheumatica in adults as a new indication for Cosentyx (secukinumab). Novartis says the approval covers 150 mg for patients who had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper.